MEDITE Cancer Diagnostics, Inc. Announces Change of Auditor

molecular biomarkers

ORLANDO, Fla., May 14, 2015 (SEND2PRESS NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. ("Company," OTCQB symbol: "MDIT" / OTCBB:MDIT), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces change of auditors.

On May 13, 2015, upon the recommendation of the Company's Audit Committee, the Board of Directors of the Company engaged WithumSmith+Brown, P.C. ("WSB") as the Company's independent registered public accounting firm, beginning with the period ended March 31, 2015. WSB is one of the largest accounting firms in the Northeast, and one of the top 31 accounting firms in the U.S. The Firm has a staff of approximately 500, with more than 350 professionals and almost 250 CPAs.

After the acquisition of MEDITE Enterprise, Inc. by the former CytoCore, Inc. in 2014 the Company moved its headquarters from Chicago, Ill. to Orlando, Fla. The engaged audit firm has a local office in Orlando which is an important factor for efficient audit work.

One day before on May 12, 2015, upon the recommendation of the Company's Audit Committee, the Board of Directors of MEDITE Cancer Diagnostics, Inc. (the "Company") dismissed L.J. Soldinger Associates ("LJSA") as the Company's independent auditing firm. The dismissal was without disagreement and we thank Soldinger Associates for 8 years of audit work for the Company.

About MEDITE Cancer Diagnostics, Inc.:

MEDITE Cancer Diagnostics Inc., is a Delaware registered company consisting of wholly-own MEDITE GmbH a Germany-based company, with its subsidiaries CytoGlobe GmbH (Germany), MEDITE GmbH (Austria), MEDITE Inc. (USA)) and MEDITE sp. z o.o. (Poland). Since 1978, MEDITE has specialized in the development, manufacture and distribution of medical laboratory automation equipment and supplies for pathology, histology and cytology. For these fields, MEDITE with its 76 employees offers a complete range of devices and consumables through an established distribution network to about 70 countries. Additional information on MEDITE's products and services can be found at On April 3, 2014, MEDITE was acquired by CytoCore, Inc. a bimolecular diagnostics company engaged in the design, development, and commercialization of cost-effective cancer screening systems and Biomarkers to assist in the early detection of cancer. The name of the company changed from CytoCore, Inc. to MEDITE Cancer Diagnostics, Inc. in early December 2014.

For more information please visit:

Investor Contact:
Robert McCullough, Jr. CFO

To view the original version on Send2Press Newswire, visit:

NEWS SOURCE MEDITE Cancer Diagnostics, Inc. :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by and Copr. © 2015 Send2Press® Newswire, a service of Neotrope®.

, , , ,

Part of the Neotrope® News Network, USA.